Dataset Information


Tumor-Treating Fields Inhibit the Metastatic Potential of Osteosarcoma Cells.

ABSTRACT: The prognosis of metastatic osteosarcoma (OS) remains poor with a <20% survival rate, particularly in cases of distant (non-lung) metastases. Tumor-treating field (TTF) therapy is a novel electric field-based treatment that causes metaphase arrest and tumor cell death, with the advantage of reduced side effects compared to radiation and chemotherapy. TTF shows promise in glioblastoma and other solid tumors; however, few studies have examined its potential in the treatment of osteosarcoma. Therefore, we explored the mechanism of TTF-induced metastasis inhibition and cell death using in vitro models. TTF (1.5 V/cm, 150 kHz) was applied to U2OS and KHOS/NP OS cell lines. In addition, a 3-dimensional culture system was established using these OS cell lines. Cell migration and invasion (i.e., metastatic potential) were examined using a wound-healing scratch assay and transwell assay, respectively. Western blotting of metastasis- and angiogenesis-related proteins was performed. TTF suppressed the migration of and invasion by OS cells and inhibited the expression of epithelial markers, thereby preventing epithelial-mesenchymal transition (EMT), a hallmark of metastasis. Moreover, TTF prevented angiogenesis in human tumor endothelial cells and downregulated matrix metalloproteinase-2 (MMP2) and vascular endothelial growth factor (VEGF) expression. Therefore, TTF shows potential as an improved treatment for osteosarcoma, warranting further preclinical studies in animal models to support clinical trials.

PROVIDER: S-EPMC7502799 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5661405 | BioStudies
| S-EPMC5190045 | BioStudies
| S-EPMC6423010 | BioStudies
| S-EPMC8228595 | BioStudies
| S-EPMC5768389 | BioStudies
| S-EPMC4808036 | BioStudies
| S-EPMC4802362 | BioStudies
2008-01-01 | S-EPMC2492999 | BioStudies
| S-EPMC4337839 | BioStudies
| S-EPMC8806225 | BioStudies